# Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05985655/  
OnCo record `nct05985655` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GTAEXS617 in head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, HR-positive / HER2-negative breast cancer and triple-negative breast cancer, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting.

## Summary

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05985655 by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., with 230 participants planned, started 2023-07-06 and due to reach its primary completion in 2028-01. Interventions recorded: GTAEXS617 and SoC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05985655
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
- Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT05985655: https://clinicaltrials.gov/study/NCT05985655

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct05985655.json